Cargando…
Pathogenic variants in the healthy elderly: unique ethical and practical challenges
Genetic research into ageing, longevity and late-onset disease is becoming increasingly common. Yet, there is a paucity of knowledge related to clinical actionability and the return of pathogenic variants to otherwise healthy elderly individuals. Whether or not genetic research in the elderly should...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629947/ https://www.ncbi.nlm.nih.gov/pubmed/28341755 http://dx.doi.org/10.1136/medethics-2016-103967 |
_version_ | 1783269152571523072 |
---|---|
author | Lacaze, Paul Ryan, Joanne Woods, Robyn Winship, Ingrid McNeil, John |
author_facet | Lacaze, Paul Ryan, Joanne Woods, Robyn Winship, Ingrid McNeil, John |
author_sort | Lacaze, Paul |
collection | PubMed |
description | Genetic research into ageing, longevity and late-onset disease is becoming increasingly common. Yet, there is a paucity of knowledge related to clinical actionability and the return of pathogenic variants to otherwise healthy elderly individuals. Whether or not genetic research in the elderly should be managed differently from standard practices adapted for younger populations has not yet been defined. In this article, we provide an overview of ethical and practical challenges in preparing for a genetic study of over 14 000 healthy Australians aged 70 years or older enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank. At the time of consent, all participants in this study were free of life-threatening illness, cardiovascular disease or cognitive impairment. ASPREE is thus a cohort of healthy elderly individuals with seemingly minimal burden of genetic disease recruited without ascertainment bias. The cohort presents a unique opportunity to address the penetrance of known pathogenic variants in a population without disease symptoms; however, it also raises a number of ethical concerns regarding the interpretation and disclosure of variants with known clinical actionability. Some of the challenges include (a) how to manage the interpretation, disclosure and actioning of pathogenic variants found in otherwise healthy elderly adults without disease symptoms, (b) whether or not to disclose findings for the benefit of family members rather than elderly consented donors themselves, (c) how to manage the return of genetic findings to the elderly individuals who are now in severe cognitive decline or terminal illness, (d) how to ensure quality of information and clinical service upon disclosure of results to this demographic and (e) how to prepare for the insurance implications of disclosing genetic information under Australian law. We discuss these and other dilemmas and propose a defensible plan of management. TRIAL REGISTRATION NUMBER: ISRCTN83772183 |
format | Online Article Text |
id | pubmed-5629947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-56299472017-10-11 Pathogenic variants in the healthy elderly: unique ethical and practical challenges Lacaze, Paul Ryan, Joanne Woods, Robyn Winship, Ingrid McNeil, John J Med Ethics Genetics Genetic research into ageing, longevity and late-onset disease is becoming increasingly common. Yet, there is a paucity of knowledge related to clinical actionability and the return of pathogenic variants to otherwise healthy elderly individuals. Whether or not genetic research in the elderly should be managed differently from standard practices adapted for younger populations has not yet been defined. In this article, we provide an overview of ethical and practical challenges in preparing for a genetic study of over 14 000 healthy Australians aged 70 years or older enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank. At the time of consent, all participants in this study were free of life-threatening illness, cardiovascular disease or cognitive impairment. ASPREE is thus a cohort of healthy elderly individuals with seemingly minimal burden of genetic disease recruited without ascertainment bias. The cohort presents a unique opportunity to address the penetrance of known pathogenic variants in a population without disease symptoms; however, it also raises a number of ethical concerns regarding the interpretation and disclosure of variants with known clinical actionability. Some of the challenges include (a) how to manage the interpretation, disclosure and actioning of pathogenic variants found in otherwise healthy elderly adults without disease symptoms, (b) whether or not to disclose findings for the benefit of family members rather than elderly consented donors themselves, (c) how to manage the return of genetic findings to the elderly individuals who are now in severe cognitive decline or terminal illness, (d) how to ensure quality of information and clinical service upon disclosure of results to this demographic and (e) how to prepare for the insurance implications of disclosing genetic information under Australian law. We discuss these and other dilemmas and propose a defensible plan of management. TRIAL REGISTRATION NUMBER: ISRCTN83772183 BMJ Publishing Group 2017-10 2017-03-24 /pmc/articles/PMC5629947/ /pubmed/28341755 http://dx.doi.org/10.1136/medethics-2016-103967 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Genetics Lacaze, Paul Ryan, Joanne Woods, Robyn Winship, Ingrid McNeil, John Pathogenic variants in the healthy elderly: unique ethical and practical challenges |
title | Pathogenic variants in the healthy elderly: unique ethical and practical challenges |
title_full | Pathogenic variants in the healthy elderly: unique ethical and practical challenges |
title_fullStr | Pathogenic variants in the healthy elderly: unique ethical and practical challenges |
title_full_unstemmed | Pathogenic variants in the healthy elderly: unique ethical and practical challenges |
title_short | Pathogenic variants in the healthy elderly: unique ethical and practical challenges |
title_sort | pathogenic variants in the healthy elderly: unique ethical and practical challenges |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629947/ https://www.ncbi.nlm.nih.gov/pubmed/28341755 http://dx.doi.org/10.1136/medethics-2016-103967 |
work_keys_str_mv | AT lacazepaul pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges AT ryanjoanne pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges AT woodsrobyn pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges AT winshipingrid pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges AT mcneiljohn pathogenicvariantsinthehealthyelderlyuniqueethicalandpracticalchallenges |